Cardiva Medical scores $30M for vascular closure system

Cardiva's vascular closure system is an alternative to manual compression, the gold standard in stopping bleeding after a percutaneous procedure.

Cardiva Medical raised $30 million in equity, which will bankroll the commercial expansion of its bioabsorbable vascular closure system and advance technologies in its pipeline.

The company’s Vascade closure system picked up an FDA nod in 2013. Built on Cardiva’s collapsible disc technology, the system temporarily stops blood flow in the femoral artery during percutaneous intervention. It then delivers a resorbable collagen patch to seal the hole made in the artery without needing any intravascular components.

Vascular closure devices are an alternative method to manual compression, where a physician or nurse will apply pressure with his or her fingers directly over the site of the puncture. While effective, manual compression may take as many as 15 minutes to stop bleeding, according to The Royal Australian and New Zealand College of Radiologists.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Vascade’s PMA approval was based on a 420-patient trial in which the device beat out manual compression in both safety and efficacy for patients receiving percutaneous procedures through the femoral artery.

RELATED: Vascular closure player Cardiva gets $12.5M, J&J exec to commercialize

"Vascade has demonstrated an unprecedented safety profile for patients—which is fueling Cardiva's rapid growth rate," said Michael Bornitz of Luther King Capital Management, a new investor that participated in the round. "We are excited to be part of that growth story and the expansion of Cardiva's technology into new areas."

Existing backers PTV Healthcare Capital and the Canepa Advanced Healthcare Fund joined Luther King Capital Management in the round.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.